Legal Commentary on the GSK China Bribery Case from a China Law Perspective

ANALYSIS: The Chinese investigation of GlaxoSmithKline should serve as a wake-up call, and the shareholders of companies in China should consider undertaking internal due diligence to ensure that existing compliance programs are properly understood and implemented.